Demand for oral nicotine pouches growing fast, British American Tobacco says
Rising global demand for oral nicotine pouches are helping boost sales for cigarette maker British American Tobacco (BAT), which has nudged up its full-year forecast.
The Velo brand is growing the fastest within its so-called 'new category', which includes non-tobacco products like vapes, the business said.
The pouches come in a variety of flavours and strengths and are designed to be placed between the gum and lip so nicotine can be absorbed through the mouth.
Tadeu Marroco, BAT's chief executive, said he was 'excited' by the launch of loyalty scheme Velo Plus in the US.
'Globally, Velo continues to gain volume share in this fast-growing category, driven by the US and our continued leadership position in AME (Americas & Europe),' he said, highlighting a strong performance in the UK, Scandinavia and Poland.
BAT said it was expecting full-year revenues to grow between 1% and 2% following a stronger-than-expected half-year performance. It had previously forecast growth of 1%.
The company continues to make the bulk of its sales from traditional cigarettes, which include the Pall Mall and Camel brands.
It said the segment remained 'under pressure' with the volume of sales about 9% lower across the industry over the year to date, but that it was gaining market share for brands including Lucky Strike.
Mr Marroco said BAT's vape sales were being affected by 'illicit' products in the US and Canada, which were driving down sales of legal devices.
BAT has previously warned that customers turning to illegal disposable vapes was hurting sales of its own vape product, Vuse, and urged a government crackdown on the market.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 days ago
- Yahoo
Altria Trades at a Bargain: Is it a Good Time to Buy the Stock?
Altria Group, Inc. MO is currently trading at an attractive discount compared to its industry peers and the broader market, making it a potential value pick for long-term investors. MO stock trades at a forward 12-month price-to-earnings (P/E) ratio of 10.81, notably lower than the industry average of 15.73 and the S&P 500's average of 21.85. Backing this valuation, the stock holds a Zacks Value Score of B, underscoring its strong fundamentals and appealing valuation profile. Image Source: Zacks Investment Research When compared to leading competitors, Altria's relative undervaluation stands out even more. Philip Morris International Inc. PM and Turning Point Brands TPB trade at significantly higher forward P/E ratios of 21.18 and 21.07, respectively. Meanwhile, British American Tobacco p.l.c. BTI trades at a slightly lower P/E of 10.49, still comparable to Altria. Despite favorable valuations, MO's recent stock performance suggests a possible entry point. The stock has gained 1.8% over the past three months, underperforming the industry average growth of 17.1%, the S&P 500's 5.4% return, and competitors like Philip Morris (+19%), Turning Point Brands (+30.8%), and British American Tobacco (+18.5%). Image Source: Zacks Investment Research As of June 17, 2025, Altria stock closed at $58.99, approximately 3.7% below its 52-week high of $61.26 (hit on May 7, 2025). Importantly, MO is trading above both its 50-day and 200-day moving averages, signaling underlying bullish momentum and investor confidence. Image Source: Zacks Investment Research With a combination of undervaluation, solid fundamentals, and potential technical upside, Altria may offer a compelling opportunity for value-focused investors looking to capitalize on the evolving tobacco landscape. Altria is accelerating its shift toward a smoke-free future, with its oral nicotine pouch brand on! emerging as a key growth engine. In the first quarter of 2025, on! shipments surged 18% year over year, surpassing 39 million cans. The brand gained 1.8 share points in the oral tobacco category, reaching 8.8%, while also increasing its nicotine pouch market share to 17.9%. These gains came despite higher retail pricing and optimized promotional spending, underscoring on!'s strong brand equity and consumer loyalty. This momentum reflects Altria's successful efforts to align its product portfolio with evolving consumer demand for reduced-risk products (RRPs). Similar to Altria, major tobacco companies such as Philip Morris, British American Tobacco and Turning Point Brands are also accelerating their transition toward smoke-free pricing power remains a critical pillar of Altria's growth strategy. The company continues to leverage strategic price increases to offset soft volumes in traditional cigarette segments and navigate a challenging regulatory landscape. In the first quarter, higher pricing supported revenue growth across both the Smokeable Products and Oral Tobacco segments. The company's ability to sustain profitability — even amid cigarette volume declines — demonstrates its pricing resilience. Altria projects 2025 adjusted earnings per share (EPS) between $5.30 and $5.45, reflecting up to 5% year-over-year growth from a base of $5.19 in 2024 (excluding intangible asset amortization), reinforcing the strength of its operating drive long-term value creation, Altria has introduced its 'Optimize & Accelerate' initiative, a forward-looking program designed to improve speed, agility and cost efficiency. The initiative enables the company to reinvest in innovation and support its smoke-free transformation. In addition, Altria is actively retooling its e-vapor platform through NJOY, following recent regulatory setbacks. Altria remains committed to offering science-based, regulated vapor products that meet the evolving preferences of adult consumers. These strategic moves position Altria to lead the next generation of nicotine innovation. Reflecting positive sentiment around Altria, the Zacks Consensus Estimate for EPS has seen upward revisions. Over the past 30 days, the estimate for the current year has increased by 4 cents to $5.39, while the estimate for next year has risen by a cent to $5.55. These upward revisions signal improving sentiment among analysts. Based on current projections, MO is expected to deliver year-over-year EPS growth of 5.3% this year and 3% next year. (Find the latest EPS estimates and surprises on Zacks Earnings Calendar.) Image Source: Zacks Investment Research Given Altria's attractive valuation, solid earnings outlook, and strategic push toward smoke-free products, the stock appears well-positioned for value-focused investors seeking stable returns in a transforming industry. While regulatory headwinds and market competition persist, MO's strong pricing power, growing presence in reduced-risk products, and favorable analyst revisions suggest a compelling long-term opportunity in the tobacco space. At present, Altria carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Altria Group, Inc. (MO) : Free Stock Analysis Report Philip Morris International Inc. (PM) : Free Stock Analysis Report British American Tobacco p.l.c. (BTI) : Free Stock Analysis Report Turning Point Brands, Inc. (TPB) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Bloomberg
4 days ago
- Bloomberg
Tobacco Firm Reynolds Rolls Back DEI Plans After Activist Attack
Reynolds American Inc., the 150-year-old maker of Camel cigarettes and Vuse vapes, said it is rolling back US diversity, equity and inclusion programs, two weeks after anti-DEI crusader Robby Starbuck singled out the company for action. Reynolds, which was purchased by London-listed British American Tobacco Plc in 2017, will cease participation in the Human Rights Campaign Foundation's Corporate Equality Index which measures LGBTQ workplace practices, end sponsorship of Pride events, and end affirmative action programs that were mandated by President Joe Biden's administration, the company said in a letter to employees Wednesday that was shared with Bloomberg.
Axios
4 days ago
- Axios
Exclusive: Northrop launches "Beacon" autonomy partnership using Model 437 aircraft
Northrop Grumman is collaborating with at least four other companies to more-quickly test and deliver autonomy under a previously undisclosed initiative dubbed Beacon. Why it matters: " There are a lot of new companies, particularly in the AI space and the autonomy space, that are out there doing a lot of very interesting things," Tom Jones, the president of Northrop's aeronautics systems sector, told Axios at the Paris Air Show. "There's been this idea that with some of these small companies — these new entrants — it's 'us versus them.' It's an 'either or,'" he added. "I don't think it is." State of play: The Beacon test bed involves digital environments and real-world trials using a modified Model 437 Vanguard aircraft made by Northrop subsidiary Scaled Composites. Flights are expected this year. Beacon was realized using internal research-and-development money. The intrigue: Shield AI, maker of the V-BAT drone and Hivemind autonomy software, is among the initial round of partners. Three other memorandums of agreement have been signed. A few more are in the pipeline. "We know them. We can work well together. We know what their product does," Jones said. "We're able to very rapidly show customers: Here's what this capability can bring." Zoom out: Unmanned technologies and other smart machinery are in high demand around the world. The U.S. Air Force wants robo-wingmen flying alongside its F-35s and -47s. The Navy, meanwhile, wants its warships flanked by drone boats toting jammers, interceptors and communication relays. The bottom line: "We want to dispel this idea that big companies can't move fast, can't be innovative," Jones said.
